Craig-Hallum Downgrades Meridian Biosciences (VIVO) to Hold

Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Fourth Quarter Cash Dividend, Sets Fiscal 2017 Cash Dividend Rate, and Reaffirms Fiscal 2017 Guidance

November 10, 2016 7:45 AM EST

GENERAL HIGHLIGHTS

CINCINNATI, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today:

reported fourth quarter and full-year fiscal 2016 net revenues of $47.0 million and $196.1 million, respectively, flat and an increase of 1%, respectively, from the same periods of the prior fiscal year; reported fourth quarter and full-year fiscal 2016 operating income of $8.9 million and $51.4 million, respectively, decreases of 33% and 8%, respectively, from the same periods of the prior fiscal... More